These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 34953601)

  • 1. Re: Masayuki Hagiwara, Atsushi Fushimi, Kazuhiro Matsumoto, Mototsugu Oya. The Significance of PARP1 as a Biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma. Eur Urol. 2022;81:145-8.
    Wang Z; Zhao Y; Zhang Y
    Eur Urol; 2022 Mar; 81(3):e65. PubMed ID: 34953601
    [No Abstract]   [Full Text] [Related]  

  • 2. The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma.
    Hagiwara M; Fushimi A; Matsumoto K; Oya M
    Eur Urol; 2022 Feb; 81(2):145-148. PubMed ID: 34627641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interrogating the Significance of PARP1 Expression and PBRM1 Mutation as Biomarkers for Predicting the Response to Atezolizumab plus Bevacizumab or to Sunitinib in Patients with Clear Cell Renal Cell Carcinoma.
    Lanillos J; Santos M; Valdivia C; Mora A; Rodríguez-Antona C
    Eur Urol; 2022 Sep; 82(3):334-335. PubMed ID: 35688666
    [No Abstract]   [Full Text] [Related]  

  • 4. Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues.
    Ning XH; Gong YQ; He SM; Li T; Wang JY; Peng SH; Chen JC; Liu JY; Qi NN; Guo YL; Gong K
    Oncotarget; 2017 Jan; 8(2):3355-3363. PubMed ID: 27926518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination Strategies for Immune Checkpoint Inhibitors in PBRM1-mutant Renal Cell Carcinoma: To PARP or Not To PARP?
    Demidova EV; Ghatalia P; Arora S
    Eur Urol; 2022 Feb; 81(2):149-150. PubMed ID: 34753637
    [No Abstract]   [Full Text] [Related]  

  • 6. PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3.
    Ding L; Chen X; Xu X; Qian Y; Liang G; Yao F; Yao Z; Wu H; Zhang J; He Q; Yang B
    Cancer Immunol Res; 2019 Jan; 7(1):136-149. PubMed ID: 30401677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.
    McKay RR; Bossé D; Xie W; Wankowicz SAM; Flaifel A; Brandao R; Lalani AA; Martini DJ; Wei XX; Braun DA; Van Allen E; Castellano D; De Velasco G; Wells JC; Heng DY; Fay AP; Schutz FA; Hsu J; Pal SK; Lee JL; Hsieh JJ; Harshman LC; Signoretti S; Motzer RJ; Feldman D; Choueiri TK
    Cancer Immunol Res; 2018 Jul; 6(7):758-765. PubMed ID: 29748390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Tumor Growth and Sensitization to Sunitinib by RNA Interference Targeting Programmed Death-ligand 1 in Mouse Renal Cell Carcinoma RenCa Model.
    Hara T; Miyake H; Hinata N; Fujisawa M
    Anticancer Res; 2019 Sep; 39(9):4737-4742. PubMed ID: 31519573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.
    Kawakami F; Sircar K; Rodriguez-Canales J; Fellman BM; Urbauer DL; Tamboli P; Tannir NM; Jonasch E; Wistuba II; Wood CG; Karam JA
    Cancer; 2017 Dec; 123(24):4823-4831. PubMed ID: 28832979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concordance of PD-1 and PD-L1 (B7-H1) in paired primary and metastatic clear cell renal cell carcinoma.
    Eckel-Passow JE; Ho TH; Serie DJ; Cheville JC; Houston Thompson R; Costello BA; Dong H; Kwon ED; Leibovich BC; Parker AS
    Cancer Med; 2020 Feb; 9(3):1152-1160. PubMed ID: 31829518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PBRM1 and BAP1 as novel targets for renal cell carcinoma.
    Brugarolas J
    Cancer J; 2013; 19(4):324-32. PubMed ID: 23867514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-497-5p down-regulation increases PD-L1 expression in clear cell renal cell carcinoma.
    Qu F; Ye J; Pan X; Wang J; Gan S; Chu C; Chu J; Zhang X; Liu M; He H; Cui X
    J Drug Target; 2019 Jan; 27(1):67-74. PubMed ID: 30183478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of the Pathologist in Renal Cell Carcinoma Management.
    Matar S; El Ahmar N; Laimon YN; Ghandour F; Signoretti S
    Hematol Oncol Clin North Am; 2023 Oct; 37(5):849-862. PubMed ID: 37258353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarker-Oriented Therapy in Bladder and Renal Cancer.
    Scholtes MP; Alberts AR; Iflé IG; Verhagen PCMS; van der Veldt AAM; Zuiverloon TCM
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Evolving Role for AXL in Metastatic Renal Cell Carcinoma.
    Hahn AW; George DJ; Agarwal N
    Clin Cancer Res; 2021 Dec; 27(24):6619-6621. PubMed ID: 34598944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma.
    Ueda K; Suekane S; Kurose H; Chikui K; Nakiri M; Nishihara K; Matsuo M; Kawahara A; Yano H; Igawa T
    Urol Oncol; 2018 Nov; 36(11):499.e9-499.e16. PubMed ID: 30131293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.
    Krieger T; Pearson I; Bell J; Doherty J; Robbins P
    Diagn Pathol; 2020 Jan; 15(1):6. PubMed ID: 32000815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1, PARP1, and MMRs as potential therapeutic biomarkers for neuroendocrine cervical cancer.
    Ji X; Sui L; Song K; Lv T; Zhao H; Yao Q
    Cancer Med; 2021 Jul; 10(14):4743-4751. PubMed ID: 34076351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-PD-1/PD-L1 therapy for renal cell carcinoma: challenges in the development of predictive biomarkers.
    Kato R; Obara W
    Expert Rev Anticancer Ther; 2022 Jul; 22(7):667-669. PubMed ID: 35670624
    [No Abstract]   [Full Text] [Related]  

  • 20. Soluble Ligand of the Immune Checkpoint Receptor (sPD-L1) in Blood Serum of Patients with Renal Cell Carcinoma.
    Kushlinskii NE; Gershtein ES; Morozov AA; Goryacheva IO; Filipenko ML; Alferov AA; Bezhanova SD; Bazaev VV; Kazantseva IA
    Bull Exp Biol Med; 2019 Jan; 166(3):353-357. PubMed ID: 30627905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.